Wed, October 25, 2017
Tue, October 24, 2017
Mon, October 23, 2017
Fri, October 20, 2017
Thu, October 19, 2017
Wed, October 18, 2017
Tue, October 17, 2017
Mon, October 16, 2017
Fri, October 13, 2017
Thu, October 12, 2017

Alethia Young Maintained (BMRN) at Buy with Increased Target to $124 on, Oct 19th, 2017


//stocks-investing.news-articles.net/content/201 .. th-increased-target-to-124-on-oct-19th-2017.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Alethia Young of Credit Suisse, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $114 to $124 on, Oct 19th, 2017.

Alethia has made no other calls on BMRN in the last 4 months.



There are 5 other peers that have a rating on BMRN. Out of the 5 peers that are also analyzing BMRN, 2 agree with Alethia's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Kennen MacKay of "RBC Capital" Initiated at Hold and Held Target at $93 on, Friday, September 15th, 2017
  • Vincent Chen of "Bernstein" Initiated at Hold and Held Target at $89 on, Thursday, July 27th, 2017


These are the ratings of the 3 analyists that currently disagree with Alethia


  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $117 on, Friday, October 6th, 2017
  • Christopher Raymond of "Piper Sandler" Initiated at Buy on, Thursday, September 14th, 2017
  • Josh Schimmer of "Evercore ISI Group" Initiated at Buy on, Thursday, August 17th, 2017

Publication Contributing Sources